Rexahn Pharmaceuticals, Inc. (NYSE Amex:RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced the presentation of data from its proof of concept study with lead CNS compound Serdaxin® at the 49th American College of Neuropsychopharmacologists (ACNP) Annual Meeting, held in Miami Beach, FL, December 5-9, 2010 at the Fountainbleau Resort.
“Results of a Proof-of-Concept, Dose-Finding, Double-blind, Placebo-Controlled Study of Serdaxin in Subjects with Major Depressive Disorder.”
Data on the antidepressant activity of Serdaxin from the Phase IIa study were presented yesterday by Dr. Joshua Rosenthal, one of the co-authors of the study, in a poster entitled, "Results of a Proof-of-Concept, Dose-Finding, Double-blind, Placebo-Controlled Study of Serdaxin in Subjects with Major Depressive Disorder."
"Serdaxin represents a new mechanism and approach to anti-depression therapy by enhancing both the serotonin and dopamine activity of neural transmitters. We believe this approach has the potential to help a broader spectrum of patients than the currently marketed therapeutics," said Rick Soni, President and Chief Operating Officer, Rexahn.
Throat problems linked to decreased baroreflex sensitivity